CA-MIRO
28.4.2022 13:02:12 CEST | Business Wire | Press release
Miro , the online platform accelerating innovation through visual collaboration, today announced Miro Next , an all-virtual event revealing the next big thing for hybrid teams through the latest product and partner developments from the company. Miro Next will take place on May 18, 2022, at 8am PST / 5pm CEST and is purposefully designed to empower global teams to do more together.
Everyone is looking for new ways to succeed and thrive in today’s hybrid work environments. Some of the secrets to success include meetings that are more inclusive and interactive – blurring the lines between in-person and the virtual experience. Companies will need custom integrations between critical applications to help drive productivity and simplify the user experience, and more and more organizations will adopt agile practices that increase teamwork and speed innovation. Miro Next will explore these strategies, along with a host of updates on product features and enhancements, all designed to help organizations make hybrid work.
The event will kick off with a keynote presentation by Varun Parmar, Miro’s Chief Product Officer. Joined onstage with Miro partners and featured speakers, including Jeetu Patel of Cisco and Megan Cook of Atlassian, Parmar will show how Miro’s digital whiteboard is just the beginning of the future of visual collaboration.
“Miro Next will help us rediscover how to put people at the center of hybrid work, and in doing so, drive deeper engagement and collaboration among teams,” said Parmar. “I hope that teams all around the world will join us for this one-of-a-kind experience in just a few weeks.”
Miro Next will also feature a presentation led by Thor Mitchell, Miro’s Head of Product, Developer Platform, giving attendees an up-close-and-personal look at the next generation of Miro’s Developer Platform, and why it’s the perfect product to create an integrated collaboration experience that’s quick, easy, and seamless. The Miro Developer Platform was created three years ago to give any individual or enterprise the ability to build plugins and third-party integrations, and embed live Miro boards into other apps using Miro’s open API and SDKs. The Miro Developer Platform unlocks new, custom workflows to enhance the collaborative experience. At Miro Next, Airtable, ClickUp and others will join Mitchell to show how the Miro Developer Platform has unlocked new ways to harness visual collaboration using Miro and what they’re planning in the future.
In addition to learning about the future of visual collaboration from Miro product leaders and partners, Miro Next attendees will get exclusive access to breakout sessions to share ideas, ask questions, and connect with other Miro users who are seeking new ways to co-create with their teams, both synchronously and asynchronously. Miro Next breakout sessions include:
- The Road to Accessibility: A Collaborative Journey - Join Phil Strain, Miro Lead Product Manager for Accessibility and Design, and Sheri Byrne-Haber, VMWare Senior Staff Architect for Accessibility, to explore how an inclusive mindset can be a game-changer when it comes to company and end-user engagement.
- The Hybrid Workplace: Securing and Managing Collaboration In This New Way of Working - This thought leadership panel will include industry experts from Miro, Netskope, and Onna, sharing their top insights and practices for securing and managing hybrid workforces, while creating frictionless environments that help drive collaboration and creativity.
- Connected and Aligned: Your Hybrid Team in Miro - Join Miro’s team of customer education experts to learn how to use Miro features and skills to include all voices in collaborative work and create a one-stop Miro board for teams to gather information, share resources, and align expeditiously on what’s most important.
Miro Next will help all teams jump from “what now?” to “what’s next?” and explore their collaborative potential. Be among the first to preview new Miro features and get a sneak peek into the modern visual collaboration ecosystem:
- WHEN : May 18, 2022, 8 am PT/ 5 pm CET
- WHAT : One highlight-filled keynote session (60 minutes) and three, exclusive breakout sessions (60 minutes each)
- HOW : It’s virtual! RSVP for free at miro.com/next
About Miro
Miro is an online, visual collaboration platform designed to unlock creativity and accelerate innovation among teams of all kinds. The platform’s infinite canvas enables teams to lead engaging workshops and meetings, design products, brainstorm ideas, and more. Miro, co-headquartered in San Francisco and Amsterdam, serves more than 30M users worldwide, including 99% of the Fortune 100. Miro was founded in 2011 and currently has more than 1,400 employees in 10 hubs around the world. To learn more, please visit https://miro.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220428005447/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom